Abstract
Twenty-nine patients aged 60-75 years with newly diagnosed acute myelogenous leukemia (AML) were randomized to receive BHAC-DM either at a reduced dose (S-1 group, n = 13; BHAC 150 mg/m2 1-7 day, DNR 30 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day) or the conventional dose (S-2 group, n = 16; BHAC 200 mg/m2 1-7 day, DNR 40 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day). On day 7, patients were given therapy for 2 more days if the ratio of blasts in their bone marrow was more than 15%. Granulocyte-colony stimulating factor was injected when the leukocyte count decreased below 1,000/microliter. The rates of complete remission were 46.2% in the S-1 group and 43.8% in the S-2 group. No significant differences in response distinguished the 2 groups. The mortality rate during myelosuppression was 1/13 in the S-1 group and 1/16 in the S-2 group. The rate of treatment-related death was 10.1% for all patients. Grade-4 adverse effects were not seen in any of the patients. We concluded that the conventional dose of BHAC-DM was as acceptable as the reduced dose in elderly patients with AML.
| Original language | English |
|---|---|
| Pages (from-to) | 109-114 |
| Number of pages | 6 |
| Journal | [Rinshō ketsueki] The Japanese journal of clinical hematology |
| Volume | 41 |
| Issue number | 2 |
| Publication status | Published - 2000 |
| Externally published | Yes |
Fingerprint
Cite this
A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients. / Mori, M.; Nisimura, H.; Urabe, A.; Tamura, K.; Makino, S.; Okabe, K.; Tomiyama, J.; Hara, M.; Tanimoto, M.; Kikuchi, M.; Hamaguchi, H.; Sato, H.; Saburi, Y.
In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 41, No. 2, 2000, p. 109-114.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients
AU - Mori, M.
AU - Nisimura, H.
AU - Urabe, A.
AU - Tamura, K.
AU - Makino, S.
AU - Okabe, K.
AU - Tomiyama, J.
AU - Hara, M.
AU - Tanimoto, M.
AU - Kikuchi, M.
AU - Hamaguchi, H.
AU - Sato, H.
AU - Saburi, Y.
PY - 2000
Y1 - 2000
N2 - Twenty-nine patients aged 60-75 years with newly diagnosed acute myelogenous leukemia (AML) were randomized to receive BHAC-DM either at a reduced dose (S-1 group, n = 13; BHAC 150 mg/m2 1-7 day, DNR 30 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day) or the conventional dose (S-2 group, n = 16; BHAC 200 mg/m2 1-7 day, DNR 40 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day). On day 7, patients were given therapy for 2 more days if the ratio of blasts in their bone marrow was more than 15%. Granulocyte-colony stimulating factor was injected when the leukocyte count decreased below 1,000/microliter. The rates of complete remission were 46.2% in the S-1 group and 43.8% in the S-2 group. No significant differences in response distinguished the 2 groups. The mortality rate during myelosuppression was 1/13 in the S-1 group and 1/16 in the S-2 group. The rate of treatment-related death was 10.1% for all patients. Grade-4 adverse effects were not seen in any of the patients. We concluded that the conventional dose of BHAC-DM was as acceptable as the reduced dose in elderly patients with AML.
AB - Twenty-nine patients aged 60-75 years with newly diagnosed acute myelogenous leukemia (AML) were randomized to receive BHAC-DM either at a reduced dose (S-1 group, n = 13; BHAC 150 mg/m2 1-7 day, DNR 30 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day) or the conventional dose (S-2 group, n = 16; BHAC 200 mg/m2 1-7 day, DNR 40 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day). On day 7, patients were given therapy for 2 more days if the ratio of blasts in their bone marrow was more than 15%. Granulocyte-colony stimulating factor was injected when the leukocyte count decreased below 1,000/microliter. The rates of complete remission were 46.2% in the S-1 group and 43.8% in the S-2 group. No significant differences in response distinguished the 2 groups. The mortality rate during myelosuppression was 1/13 in the S-1 group and 1/16 in the S-2 group. The rate of treatment-related death was 10.1% for all patients. Grade-4 adverse effects were not seen in any of the patients. We concluded that the conventional dose of BHAC-DM was as acceptable as the reduced dose in elderly patients with AML.
UR - http://www.scopus.com/inward/record.url?scp=0034132901&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034132901&partnerID=8YFLogxK
M3 - Article
C2 - 10723239
AN - SCOPUS:0034132901
VL - 41
SP - 109
EP - 114
JO - [Rinsho ketsueki] The Japanese journal of clinical hematology
JF - [Rinsho ketsueki] The Japanese journal of clinical hematology
SN - 0485-1439
IS - 2
ER -